Canton Strategic Holdings (CNTN) Fair Value & Analysis
Healthcare · US · Market cap $234M
Canton Strategic Holdings
CNTN · US
Fair value as of: Jul 15, 2026
From 1 valuation models · updated today
Share price −25.6% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.17 – $7.71 · fair‑value band $2.42 – $4.85 · the $2.30 price screens below the $3.25 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Canton Strategic Holdings (CNTN) currently trades at $2.30, while our model-based Fair Value estimate is $3.25 — implying the stock looks roughly 41.2% undervalued today. We read business quality at 19/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
It earns a return on equity of -34.4%. The balance sheet holds a net cash position of $17.0M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $2.42 (bear case) to $4.85 (bull case); at $2.30, the current price sits below that range. The share trades about 75% below its 52-week high and 113% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside — at 41%, CNTN screens cheaper than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States. It operates in two segments, Digital Asset Treasury and Clinical Stage Bio-technology. The company is involved in the operation of Canton Coin-centric digital asset treasury strategies, including validator operations and network participation; application support and strategic investments; collaboration and ecosystem advancement; capital raising and treasury expansion; token management - locking, lending, and options; Canton Foundation; and governance and risk management. It also researches and develops GV104, a buccal film formulation of nalmefene for the treatment of respiratory depression and prophylactic protection against synthetic opioid exposure in military and first responders; and GV023, an oral anti-tumor necrosis factor-alpha monoclonal antibody that addresses critical limitation of IV gold standard for the treatment of repeated …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Canton Strategic Holdings reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$35.9M in FY2025.
Is CNTN fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Canton Strategic Holdings (CNTN) undervalued?
What is the fair value of CNTN?
What is the quality score of CNTN?
What is the net profit margin of CNTN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Canton Strategic Holdings analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.